Company continues to leverage efficiencies of its unified platform,
expanding the richness, ease and detailed nature of clinical trial
information through site performance metrics and standard reporting
capabilities
CLEVELAND, Oct. 1 /PRNewswire-FirstCall/ -- DATATRAK International,
Inc. (Nasdaq: DATA), a technology and services company focused on global
eClinical solutions for the clinical trials industry, today announced the
newest release of its DATATRAK eClinical(TM) product suite. This release of
the Company's unified platform for global clinical trials, having
successfully passed internal testing and validation requirements was placed
into production on Saturday, September 27, 2008.
Several significant incremental advancements are represented by this
version of DATATRAK eClinical. First and foremost is the ease with which
extensively detailed information about clinical trials can be obtained with
this product suite. An example of the information that is automatically
tracked by this platform includes metrics on investigative site
performance. Such information is critical to clinical trial sponsors when
deciding where to place specific clinical studies as efficient enrollment
of patients is often the reason why clinical trial timeframes are delayed
and projections are missed, resulting in an increased overall cost for
research and development. With this version of DATATRAK eClinical, as long
as this platform is consistently used, clinical trial sponsors will be able
to characterize the historic quality of a research site before the clinical
trial is started, potentially avoiding a key delay factor in drug and
device development worldwide.
This version of DATATRAK eClinical now contains capabilities for
Japanese/Kanji-character translation, making this platform more readily
accepted in the third largest clinical trial market in the world. The
clinical trials recently won by NTT DATA in Japan will initiate enrollment
during the Fourth Quarter of 2008 with this new release.
A complete listing of the new and enhanced functionalities of the
eClinical product suite can be found by going to the following link:
http://www.datatrak.net/newreleases/v7/ .
"Our unified architectural platform continues to allow for efficient
and rapid development and expansion of our product suite capabilities,
probably more than any other software in this industry," stated Dr. Jeffrey
A. Green, Chief Executive Officer of DATATRAK International, Inc.
"Importantly, we can accomplish all of this without having to integrate
with unrelated applications, thereby saving our customers time and money
from alternative approaches. We believe the capability to quantify in an
effortless manner quantitative statistics on site metrics and performance
in clinical trials will be increasingly viewed as important by our
customers and represents a future differentiating capability within this
market."
About DATATRAK International, Inc.
DATATRAK International, Inc. is a worldwide technology company focused
on the provision of multi-component eClinical solutions and related
services for the clinical trials industry. The Company delivers a complete
portfolio of software products that were created in order to accelerate
clinical research data from investigative sites to clinical trial sponsors
and ultimately the United States Food and Drug Administration (FDA), faster
and more efficiently than manual methods or loosely integrated
technologies. DATATRAK's eClinical software suite can be deployed worldwide
through an ASP offering or in a licensed Enterprise Transfer model that
fully empowers its clients. The DATATRAK software suite and its earlier
versions have successfully supported hundreds of international clinical
trials involving thousands of clinical research sites and encompassing tens
of thousands of patients in 59 countries. DATATRAK International, Inc.'s
product suite has been utilized in some aspect of the clinical development
of 16 drugs and one medical device that have received regulatory approval
from either the FDA or counterpart European bodies. DATATRAK International,
Inc. has offices located in Cleveland, Ohio and Bryan, Texas. Its common
stock is listed on the NASDAQ Stock Market under the ticker symbol "DATA".
Visit the DATATRAK International, Inc. web site at http://www.datatrak.net .
Except for the historical information contained in this press release,
the statements made in this release are forward-looking statements. These
forward-looking statements are made based on management's expectations,
assumptions, estimates and current beliefs concerning the operations,
future results and prospects of the Company and are subject to
uncertainties and factors (including those specified below) which are
difficult to predict and, in many instances, are beyond the control of the
Company. Factors that may cause actual results to differ materially from
those in the forward-looking statements include the limited operating
history on which the Company's performance can be evaluated; the ability of
the Company to continue to enhance its software products to meet customer
and market needs; fluctuations in the Company's quarterly results; the
viability of the Company's business strategy and its early stage of
development; the timing of clinical trial sponsor decisions to conduct new
clinical trials or cancel or delay ongoing trials; the Company's dependence
on major customers; government regulation associated with clinical trials
and the approval of new drugs; the ability of the Company to compete in the
emerging EDC market; losses that potentially could be incurred from
breaches of contracts or loss of customer data; the inability to protect
intellectual property rights; delisting of the Company's common shares from
the Nasdaq due to our failure to continue to meet applicable Nasdaq Capital
Market requirements; the infringement upon other's intellectual property
rights; the Company's success in integrating its acquisition's operations
into its own operations and the costs associated with maintaining and/or
developing two product suites; the outcome of the Company's disputes with
former shareholders of ClickFind, Inc.; the effects and outcomes of the
Company's exploration of potential opportunities directed at maximizing
shareholder value; and general economic conditions such as the rate of
employment, inflation, interest rates and the condition of capital markets.
This list of factors is not all inclusive. In addition, the Company's
success depends on the outcome of various strategic initiatives it has
undertaken, all of which are based on assumptions made by the Company
concerning trends in the clinical research market and the health care
industry. The Company undertakes no obligation to update publicly or revise
any forward-looking statement.
SOURCE DATATRAK International, Inc.
 back to top
Related links:
http://www.datatrak.net
http://www.datatrak.net/newreleases/v7/
CONTACT:
Jeffrey A. Green, Pharm.D., FCP, Chief
Executive Officer, +1-440-443-0082 x112, or Ray Merk, Chief
Financial Officer, +1-440-443-0082 x181, both of DATATRAK
International, Inc.; or Neal Feagans, Investor Relations, Feagans
Consulting, Inc, +1-303-449-1184, for DATATRAK International,
Inc.
|
